World Health Organization Sounds Warning Over Critical Lack of Obesity Jabs

Less than one in 10 people who could benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it releases its initial advice on the medications.

Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for more widespread and fairer access to these injectable treatments.

According to forecasts, more than two billion will be obese by 2030 if no action is taken.

"Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with holistic and continuous care," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major obstacles to widespread availability to the jabs that can aid individuals in losing substantial weight, says the agency.

GLP-1 Therapy Scarcity

Even in the current most optimistic case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, according to the WHO.

The guideline encourages countries and companies to widen availability, through strategies like patent sharing.

The intellectual property rights on the active ingredient – the core component of a leading brand – is due to expire in several nations in 2026.

The Way Weight-Loss Drugs Work

These medications mimick a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people eat less.

Individuals typically start to lose weight after several weeks of commencing the once-weekly jabs.

Evidence suggests patients may put most of the weight back on within a year of stopping the medication, when their normal hunger resume.

To be carrying excess weight raises your likelihood for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.